Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.

@article{Diringer2008RiskOT,
  title={Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.},
  author={Michael N Diringer and Brett E. Skolnick and Stephan A. Mayer and Thorsten Steiner and Stephen M Davis and Nikolai C. Brun and J P Broderick},
  journal={Stroke},
  year={2008},
  volume={39 3},
  pages={850-6}
}
BACKGROUND AND PURPOSE Recombinant activated factor VII (rFVIIa) reduces hematoma expansion and improves outcome after intracerebral hemorrhage (ICH), with an apparent increase in nonfatal thromboembolic events (TEs) with higher doses. Despite low incidences of such events in rFVIIa-treated hemophiliacs, the frequency in older patients with more atherosclerosis and immobility has yet to be defined. METHODS Data were pooled from 3 randomized placebo-controlled studies in patients diagnosed… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Similar Papers

Loading similar papers…